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Abstract
Background: Upon viral recognition, innate and adaptive antiviral immune responses are initiated by genital epithelial cells
(ECs) to eradicate or contain viral infection. Such responses, however, are often accompanied by inflammation that
contributes to acquisition and progression of sexually transmitted infections (STIs). Hence, interventions/factors enhancing
antiviral protection while reducing inflammation may prove beneficial in controlling the spread of STIs. Serine antiprotease
trappin-2 (Tr) and its cleaved form, elafin (E), are alarm antimicrobials secreted by multiple cells, including genital epithelia.
Methodology and Principal Findings: We investigated whether and how each Tr and E (Tr/E) contribute to antiviral
defenses against a synthetic mimic of viral dsRNA, polyinosine-polycytidylic acid (polyI:C) and vesicular stomatitis virus. We
show that delivery of a replication-deficient adenovector expressing Tr gene (Ad/Tr) to human endometrial epithelial cells,
HEC-1A, resulted in secretion of functional Tr, whereas both Tr/E were detected in response to polyI:C. Moreover, Tr/E were
found to significantly reduce viral replication by either acting directly on virus or through enhancing polyI:C-driven antiviral
protection. The latter was associated with reduced levels of pro-inflammatory factors IL-8, IL-6, TNFa, lowered expression of
RIG-I, MDA5 and attenuated NF-kB activation. Interestingly, enhanced polyI:C-driven antiviral protection of HEC-Ad/Tr cells
was partially mediated through IRF3 activation, but not associated with higher induction of IFNb, suggesting multiple
antiviral mechanisms of Tr/E and the involvement of alternative factors or pathways.
Conclusions and Significance: This is the first evidence of both Tr/E altering viral binding/entry, innate recognition and
mounting of antiviral and inflammatory responses in genital ECs that could have significant implications for homeostasis of
the female genital tract.
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Introduction
Genital epithelial cells (ECs) provide the first line of defense
against sexually-transmitted infections (STIs) [1,2]. Upon viral
sensing through pattern-recognition receptors (PRRs), ECs initiate
innate and adaptive immune responses that serve to eradicate or
contain viral pathogens [3,4]. ECs can directly respond to viruses
and viral pathogen-associated molecular patterns (PAMPS) by
secreting innate protective factors, including defensins and
cathelicidins [5] as well as members of the whey-acidic protein
(WAP) family [6]. Of the 18 human WAP proteins, only a few
have been well characterized to date [7], and among the better
understood are serine antiproteases elafin (E) with its precursor,
trappin-2 (Tr), as well as secretory leukocyte protease inhibitor
(SLPI), and prostate stromal protein 20 kDa (ps20) [7,8].
The physiological role of serine antiproteases has been
extensively studied over the past two decades [9], mainly due to
their contribution to homeostatic equilibrium through the control
of proteases, inflammation, and infections [10,11]. Together with
other proteins, such as snake venom neurotoxins [12] and whey
acidic protein [13], serine antiproteases share an evolutionary
conserved canonical cysteine-rich four-disulfide core (FDC)
domain, or the WAP domain, involved in protease inhibition
[14]. Trappin-2 (9.9 kDa) (or pre-elafin) is a secreted and
unglycosylated protein of 95-amino acids (aa) [15] that contains
an N-terminal cementoin domain (38-aa) [16] and elafin
(5.9 kDa), a C-terminal inhibitory WAP (57-aa) domain [14,16].
Elafin is released from the N-terminus of Tr by proteolysis,
arguably most efficiently by mast cell tryptase [17,18]. Antipro-
tease activity and wound repair were the first described properties
of Tr and E (Tr/E), similar to SLPI. Unlike ps20, SLPI along with
Tr/E are functional neutrophil serine protease inhibitors [7,11].
Inhibition of human neutrophil elastase (HNE) and proteinase 3
by the inhibitory loop on a WAP domain allows Tr/E to control
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neutrophil-rich environment. In turn, cross-linking between
repeated hexapeptide motifs (GQDPVK) on the N-terminal
portion of each Tr/E [15,19] and extracellular matrix proteins
arguably allows Tr/E to repair compromised tissue integrity
[19,20]. In addition, due to their cationic nature, but not
exclusively [21], Tr/E were shown to possess antimicrobial
activity against Gram-negative and Gram-positive bacteria
[21,22,23] and certain fungal infections [24]. Worth mentioning
is that similar to SLPI, antibacterial activity of Tr/E appeared to
be independent of their antiprotease function [22]. Later, anti-
inflammatory features of the antiproteases were also described,
showing that Tr/E and SLPI were capable of reducing activation
of NF-kB and AP-1 by altering IkB activation [25] and
proteosomal degradation [26], respectively, in response to
inflammatory and bacterial stimulation. More recent studies,
however, also reported immunomodulatory properties of Tr/E.
Indeed, depending on the environment, Tr/E can either dampen
inflammation [20,26] or promote immunostimulatory events and
prime the immune system [27,28]. Both Tr/E are found at
mucosal surfaces [6,29], in tissues [30,31,32,33,34] and multiple
cell types, including genital ECs [6,31] and regarded as alarm
antiproteases, as they are mainly produced in response to pro-
inflammatory stimuli like LPS [35], TNFa [36], and IL-1b
[31,37]. Interestingly, ECs from the female genital tract (FGT)
produce Tr/E constitutively, with uterine cells capable of
producing even greater amounts of Tr/E in response to a viral
ligand, polyinosine-polycytidylic acid (polyI:C) [6], indicating the
significance of these molecules in controlling the local milieu in the
FGT.
Viral double-stranded RNA (dsRNA) is a PAMP generated
during the life cycle of most, if not all, viruses [4,38]. Double-
stranded RNA, including viral dsRNA and its synthetic mimic
polyI:C, are recognized by at least two families of PRRs: Toll-like
receptors (TLRs), including TLR 3 [39,40], and RNA helicases,
namely retinoic acid inducible gene-I (RIG-I) [41,42] and
melanoma differentiation associated gene 5 (MDA5) [43].
Following recognition of dsRNA, activated PRRs initiate a series
of signaling events, triggering phosphorylation, homodimerization
and translocation into the nucleus of a set of transcription factors
like interferon (IFN) regulatory factor 3 (IRF3), IRF7, NF-kB, and
ATF2/c-Jun (c-Jun) [38,41,44,45]. Inside the nucleus, these
transcription factors either work independently or interact with
each other [46] in triggering the transcription of antiviral and
inflammatory gene products, such as type I IFNs and IL-8, IL-6,
and TNFa. Specifically, IRF3 alone can directly bind to the IFN-
stimulated response element in the promoter region of interferon-
stimulated genes (ISGs) and activate a set of ISGs and their
products in the absence of type I IFN production [47,48]. Such
antiviral cascade is devoid of excessive inflammatory responses and
is induced when a low viral stimulation is detected. Alternatively,
in response to a high viral load, IRF3 associates with NF-kB and c-
Jun to trigger the production of IFNb and the induction of ISGs in
an IFN-dependent mode [45,49], which also triggers robust
inflammation, target cell recruitment, and/or tissue damage due to
the production of pro-inflammatory cytokines and chemokines
along with antiviral type I IFNs molecules [39,48].
Treatment with polyI:C has been shown to induce potent
antiviral protection in vitro and in vivo, making polyI:C an attractive
candidate for microbicide or vaccine adjuvant trials against STIs
[39,40,50]. However, in addition to antiviral activity, polyI:C also
triggers the release of pro-inflammatory mediators [39,40],
therefore potentially negating its beneficial effects in the FGT.
While pro-inflammatory factors are important for immune cell
recruitment and activation, if poorly controlled, they may also be
detrimental in FGT, since acquisition and pathogenesis of
common STIs are associated with immune activation and
inflammation [51,52,53]. Hence, interventions leading to better
control of inflammatory responses may prove to be more beneficial
for increased antiviral protection and overall health in the FGT.
Recently, new evidence has accumulated on the role of Tr/E in
protection against viruses [6,29]. Indeed, Tr/E have been
associated with resistance to HIV mucosal transmission in
commercial sex workers (CSWs) in Kenya [29]. Later, Ghosh et
al. reported an anti-HIV feature of E in in vitro study [6].
Furthermore, Roghanian et al. documented that Tr expression
increased Ad/LacZ viral clearance, as well as secondary immune
responses, in a murine model in vivo [27].
Collectively, these data clearly demonstrate the importance of
Tr/E in antiviral protection, although specifically how Tr/E
contribute to antiviral immune-inflammatory responses is still
unknown. Thus, the objective of this study was to elucidate
whether and how Tr/E contribute to innate antiviral and
inflammatory responses in uterine ECs elicited by a viral ligand,
polyI:C. Here, we describe novel antiviral and immunomodula-
tory properties of Tr/E. To the best of our knowledge, this is the
first study to present evidence of Tr/E affecting host innate
recognition and modulating antiviral and inflammatory responses
in genital ECs against polyI:C.
Materials and Methods
Reagents
PolyI:C and lipopolysaccharide (LPS) were reconstituted in the
phosphate-buffered saline (PBS) and used at concentrations shown
in figures (Sigma-Aldrich, Oakville, ON, Canada). Human
recombinant (r) proteins Tr (rTr) (R&D Systems, Burlington,
ON, Canada) [15] and in-house recombinant E (rE) (described
below) were used in in vitro experiments and as reference markers
for Western blotting. The amount of Tr/E being used in this study
ranges from 0.2 to 5 mg/ml to cover the physiological levels (within
1 mg/ml) reported previously [6,29] as well as concentrations
achieved in supernatants of human endometrial carcinoma
(HEC)-1A cells infected with a replication-deficient adenovirus
(Ad) expressing human Tr gene (Ad/Tr) (over 1 mg/ml).
Cell lines
HEC-1A, Caco-2 (human colonic epithelial cells), and A549
(derived from a type II human alveolar cell carcinoma) cells [54]
were obtained from American Type Culture Collection (Rockville,
MD). HEC-1A and A549 cells were cultured in McCoy’s 5A
Medium Modified (Invitrogen Life Technologies, Burlington,
Ontario, Canada) and DMEM, respectively, supplemented with
10% fetal bovine serum (FBS), 1% HEPES, 1% l-glutamine
(Invitrogen Life Technologies), and 1% penicillin-streptomycin
(Sigma-Aldrich) at 37uCi n5 %C O 2. Caco-2 cells were cultured in
DMEM growth medium containing 5% FBS, 1% l-glutamine, 1%
penicillin-streptomycin, 5 mL NEAA, and 9.6 mL NaHCO3.
Adenoviral constructs and delivery in cell culture
The Ad constructs used in this study have been described in
detail elsewhere [55,56,57]. To express human Tr, the Ad/Tr
vector, encoding gene for 95-aa human Tr, was used [55,56]. This
Ad construct was previously called Ad/E. E1, E3-deleted empty
adenovirus Ad-dl703 (Ad/dl), coding for no transgene, was used as
a control for Ad/Tr [57]. Both Ad vectors were prepared at the
Centre for Gene Therapeutics at McMaster University (Hamilton,
ON, Canada). To generate supernatants containing Tr, HEC-1A
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Ad/Tr (Ad/Tr-cells) or Ad/dl (Ad/dl-cells) overnight at 37uCi n
Opti-MEMH I Reduced Serum Medium (Invitrogen Life Tech-
nologies), washed with PBS and incubated for 12 h in serum-
containing medium. Cells were washed again and incubated for
additional 24 h in serum-free cell culture medium. Cell-free
supernatants were used either for protein measurement by ELISA
or for antiprotease activity against HNE. Another aliquot of
supernatants was further concentrated with 3–30 kDa MWCO
centrifugal filter units (Amicon, Millipore, Billerica, MA, USA) as
per supplier’s instructions and used in in vitro studies. For routine
experiments, epithelial cells were either treated with Opti-MEM
medium alone (UT) or with MOI 50 PFU of Ad/dl or Ad/Tr at
37uC overnight. After PBS washes and rest for 4 h, cells were
incubated in serum-containing medium alone or with polyI:C for
additional 24 h.
Vesicular stomatitis virus (VSV) plaque reduction assay
and antiviral assay
Vesicular stomatitis virus (VSV-GFP), a lytic IFN-sensitive virus
expressing green fluorescent protein under the viral promoter (a
kind gift from Dr. Brian Lichty, McMaster University), was used in
a plaque reduction assay [44] to assess the role of Tr/E in antiviral
protection. This method is based on determining the ability of
VSV-GFP to replicate in cell cultures in presence of biologically
active antiviral factors, e.g., IFNs [44]. Briefly, HEC-1A cells were
seeded in 96-well culture plates and infected with Ad (Ad-cells) as
described above, followed by treatment with medium alone or
polyI:C for 24 h. Induction of antiviral response was assessed by
subsequently challenging cell monolayers in serum-free medium
with MOI 1 PFU of VSV-GFP. GFP fluorescence intensity was
visualized 24 h later on a Typhoon Trio (Amersham Bioscience,
GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) and
quantified using Image Quant 5.2 software.
MTT viability assay
MTT assay, described elsewhere [39], was used as per supplier’s
instructions to determine viability of Ad-exposed and polyI:C-
treated HEC-1A cells (Biotium Inc., Hayward, CA, USA).
ELISA assays
Cell-free supernatants were stored at 270uC until assayed for
human Tr/E, IL-8, TNFa, IL-6 with ELISA Duoset kit (R&D
Systems), human IFNb by ELISA kit from Antigenic America Inc.
(Huntington Station, NY, USA), and IFNa subtypes by VeriKine
TM
Human Interferon-Alpha Multi-Subtype ELISA Kit (Piscataway,
NJ, USA) according to the supplier’s protocol. Analytes were
quantified based on standard curves obtained using an ELISA
reader Tecan Safire ELISA reader (MTX Labs Systems Inc.). Cut
off limit for Tr/E and IL-8 was 31.25 pg/ml; for TNFa and IFNb
was 15.6 pg/ml; for IFNa subtypes was 12.5 pg/ml, and levels
detected below these limits were considered as undetectable.
Generation of recombinant human elafin
To prepare rE protein, cDNA fragments encoding the relevant
part of Tr (amino acid residues A61–Q117) were amplified from
HEC-1A cells cDNA using the following primers: 59-ACAG-
GATCCGCGCAAGAGCCAGTCAAAGGTCCA-39 and: 59-
CAGGAATTCTCACTGGGGAACGAAACAGGCCATC-39.
The amplified elafin-cDNA was gel purified, restriction digested,
and directionally subcloned into BamH I and EcoR I site of
bacteria expression vector pHAT10 (BD Biosciences, Rockville,
MD, USA) in frame to the HAT-tag. The clone was confirmed by
restriction digestion and nucleic acid sequencing of both strands.
The plasmid was transformed into Escherichia coli BL21 strain
(Codon Plus, Palo Alto, CA, USA). When the cells grew in Luria-
Bertani broth containing 100 mg/ml ampicillin to an A600 of 0.55–
0.60 at 37uC, protein expression was induced by adding isopropyl-
b-D-thiogalactopyranoside (IPTG) to a final concentration of
1 mM for 6 h. The cells were harvested by centrifugation at
2,0006g for 5 min, and cell pellets were washed once with ice-cold
PBS (pH 7.4) and resuspended in wash buffer (50 mM Na2PO4,
300 mM NaCl, pH 7.0). The desired recombinant protein, rE,
was found in the soluble fraction in pilot experiment. After
disrupting the cells by freeze-thaw and subsequently by sonication,
the lysates were centrifuged at 20,0006g for 20 min, and the
soluble fraction was collected. The soluble recombinant protein
was purified from this fraction by BD TALON metal affinity resin
(BD Biosciences, Mississauga, ON, Canada) according to the
manufacturer’s instructions and dialyzed against PBS at 4uC. The
expressed human rE was confirmed by Western blotting targeting
the HAT-tag as well as by specific antibody for human E.
Preparation of cell extracts and Western blot (WB)
analysis
Whole-cell extracts were prepared by using whole-cell extract
buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1%NP-40,
1%SDS, 16protease inhibitor (Roche, Mississauga, ON, Canada))
as per standard protocol. Protein amount was quantified using
Bradford assay with bovine serum albumin (BSA) (Sigma-Aldrich)
as a standard and Bio-Rad Dye Reagent Concentrate as a protein
stain (Bio-Rad Laboratories, Mississauga, ON, Canada). WB was
performed on a 10% polyacrylamide denaturing SDS-PAGE gel
and PVDF membranes (Amersham, Arlington Heights, IL, USA)
as per standard protocol, using the following primary antibodies:
anti-human Tr/E TRAB2O (Hycult Biotech, Uden, Netherlands),
tIRF3 FL-425 (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
pIRF3 Ser396 (Cell Signaling, Danvers, MA, USA), RIG-I #4520
(Cell Signaling), MDA-5 R470 (Cell Signaling), c-Jun (60A8) (Cell
Signaling), p-c-Jun (Ser73) (Cell Signaling), TLR3 IMG-5631-2
(Imgenex, San Diego, CA, USA), NF-kB p65 (C-20): sc-372 (Santa
Cruz), GAPDH ab9485 (Abcam) antibodies at a dilution of
1:1000, except for GAPDH (1:5000) and p-NF-kB p65 (Ser 536):
sc-33020 (Santa Cruz) (1:100). After incubation with correspond-
ing horse-radish peroxidase (HRP)-conjugated secondary antibody
(Bio-Rad Laboratories), blots were visualized using a SuperSignal
West Femto or Pico Chemiluminescent Substrate kit (Thermo
Scientific, Rockford, IL, USA). GAPDH was used as internal
loading control. Quantification of band intensities was done using
MBF_ImageJ for Microscopy Software.
Transfection and luciferase assay
HEC-1A cells (5610
5 per well) were transfected in 0.5 mL of
Opti-MEMH medium (Invitrogen Life Technologies) in a 24-well
plate with 20 ng of DNA of each of pgkb-Gal and pNF-kB-Luc or
pAP-1-Luc (Stratagene, La Jolla, CA, USA) plasmids (total DNA
40 ng per well) and 50 MOI of Ad/dl or Ad/Tr overnight at 37uC
utilizing Lipofectamine 2000 (Invitrogen Life Technologies) as per
supplier’s instructions. Pgk-b-Galactosidase plasmid was used as a
normalization control. After transfection, cells were extensively
washed with PBS and allowed to rest for 4 h followed by
stimulation with polyI:C and LPS for 2–4 h. After ligand
stimulation, cells were washed twice with cold PBS, lysed with
16 reporter buffer (Enhanced Luciferase Assay Kit (Cat #
556866, BD Pharmingen) and subjected to one freeze-thaw cycle,
after which cell lysates were collected and assayed in a 96-well
plate for luciferase (Enhanced Luciferase Assay Kit, BD Pharmin-
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Madison, WI, USA) activities separately as per supplier’s protocol,
using Opticomp I luminometer (MGM instruments).
IRF3 knockdown by RNA interference
Small interfering (siRNA) molecule (Invitrogen Life Technolo-
gies) targeting IRF3 (GenBank accession number NM_001571)
within 247–1530 ORF through the following sequences: IRF3-498
(start) CAACCGCAAAGAAGGGTTGCGTTTA, or non-target-
ing siRNA, RNAi Negative Control (medium GC content), 12935-
300, (Invitrogen Life Technologies) were used to specifically
knockdown IRF3. Transfections of siRNA (8 pmol) were done
using Lipofectamine RNAiMAX and Opti-MEMH I Reduced
Serum Medium (Invitrogen Life Technologies) as per supplier’s
instructions. HEC-1A cells, 3610
4 in a 100 ml of total volume of
complete growth medium, were transfected in a 96-well BD
Falcon culture plate (BD Biosciences) for 48 h before adding MOI
50 PFU of Ad/dl or Ad/Tr. Knockdown efficiency was monitored
using WB.
RNA extraction and real-time quantitative PCR analysis
The protocol for RNA isolation was described elsewhere [52].
Briefly, total RNA was isolated from Ad-cells cultured with
medium alone or polyI:C for 6 h, using TRIzol reagent
(Invitrogen Life Technologies) according to the supplier’s protocol.
RNA was DNase-treated with DNA-free (Ambion, Austin, TX,
USA) and complementary (cDNA) was synthesized from total
RNA using SuperScript reverse transcriptase III (Invitrogen Life
Technologies) as per supplier’s protocol. Real-time quantitative
PCR was performed in a total volume of 25 ml using 16Universal
PCR Master Mix (Applied Biosystems, Foster City, CA, USA),
5 ml of diluted cDNA, 500 nmol forward primer, 500 nmol
reverse primer (Mobix; McMaster University, ON, Canada), and
200 nmol probe in a 96-well plate. TaqMan oligonucleotide
primers and probes labeled with 6FAM at 59-end and a non-
florescent quencher at 39-end were designed using Primer Express
1.5 (Applied Biosystems) and selected following the TaqMan rules
of Applied Biosystems. The sequences were as follows: RIG-I: 59-
AGGGCTTTACAAATCCTGCTCTCTTCA-39 (probe), 59-G-
GTGTTCCAGATGCCAGAC-39 (forward), 59-TTCCGCAA-
ATGTGAAGTGTATAA-39(reverse); MDA5: 59-TTTGGCTT-
GCTTCGTGGCCC-39(probe), 59-TGATTCCCCTTCCTCA-
GATAC-39(forward), 59-TGCATCAAGATTGGCACATAGT-
39(reverse); TLR3: 59-TGTGGATAGCTCTCC-39(probe), 59-
CCGAAGGGTGGCCCTTA-39(forward), 59-AAGTTACGAA-
GAGGCTGGAATGG-39 (reverse); 18S rRNA: 59-CGGAAT-
TAACCAGACAAATCGCTCCA -39 (probe), 59-GTGCATG-
GCCGTTCTTAGTT-39 (forward), 59-TGCCAGAGTCTCG-
TTCGTTAT-39 (reverse). The expression of 18S ribosomal
RNA (rRNA) was used as an internal control. PCR was run with
the standard program: 95uC 10 min, 40 times of cycling 95uC
15 sec and 60uC 1 min in a 96-well plate with an ABI PRIZM
7900HT Sequence Detection System using the Sequence Detector
Software 2.2 (Applied Biosystems). To determine the expression of
ISG56, a semi-quantitative RT-PCR was performed with
oligonucleotide primer sequences (Mobix): 50-GACAGGAAGCT-
GAAGGAGAAA-39 (445-bp product) (forward), 59-TcTTGCAT-
TGTTTCTTCTACCACT-39 (reverse). PCR program was as
follows: 94uC for 2.5 min, 30 cycles of 94uC for 20 sec, 55uC for
30 sec, 72uC fir 1 min, 72uC for 5 min. PCR products were
electrophoresed on 2% agarose gel using a 100-bp DNA ladder
(Invitrogen Life Technologies) as a marker to identify PCR
products. The gel was stained with a loading fluorescent dye EZ-
vision N472-Q (AMRESCO Inc., Solon, OH, USA) and
visualized with UV transilluminator (Gel Doc 2000, BioRad,
Mississauga, ON, Canada). Densities of DNA bands were
quantified to signal volumes using ImageQuant 5.0.
Immunofluorescence staining
Immunofluorescence staining was performed as described
earlier [39,44], but with minor modifications. Ad-cells, grown on
an 8-well BD Falcon culture slides (BD Biosciences), were
medium- or 25 mg/ml polyI:C-treated for 4 h, fixed with 4%
paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS
for 20 min, and blocked for 1 h at ambient temperature in a
blocking solution (0.1% Triton X-100, containing 5% goat serum/
BSA). IRF3 was detected using 1:100 dilution in blocking solution
of IBL18781 (IBL, Gunma, Japan) antibody for 1 h. Negative
control rabbit immunoglobulin fraction (DakoCytomation,
Glostrup, Denmark) served as an isotype control and was diluted
to match the protein content of the primary anti-IRF3 antibody.
Secondary antibody, Alexa Fluor 488 conjugated goat anti-rabbit
IgG (Molecular Probes, Eugene, OR, USA) was added to cells in a
blocking solution for 1 h. The nuclei were visualized by staining
with propidium iodide. Images were acquired using an inverted
laser-scanning confocal microscope (LSM 510, Zeiss, Oberkochen,
Germany).
Protease inhibition assay (PIA)
This assay was performed by measuring inhibition of HNE
activity by Tr/E as was described earlier [20], but with minor
modifications. Elastase-inhibitory activity was measured in a 96-
well plate by combining cell-free undiluted supernatant (generated
as described earlier in Materials and Methods and before or after
polyI:C treatment) (final volume 10 ml/well), serially diluted each
rTr and rE, or medium alone, to a known quantity of purified
HNE (50 ng in 10 ml/well) or diluent alone (negative control), and
incubating for 30 min at 37uC. Subsequently, 50 ml of HNE
substrate, N-methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide (Sig-
ma-Aldrich), diluted to 50 mg/ml in 50 mM Tris, 0.1% Triton,
0.5 M sodium chloride, pH 8 buffer were added and the
hydrolysis was recorded by monitoring the increase of absorbance
at 405 for 15 min using a Tecan Safire ELISA reader (MTX Labs
Systems).
Statistical analysis
Data were expressed as means 6 standard deviation (SD).
Statistical analysis was performed with either unpaired Student’s t
test or a one-way analysis of variance (ANOVA) using Sigma Stat
2.03.
Results
Ad/Tr-cells secrete Tr and both Tr/E are detected in Ad/
Tr-cells supernatants in response to polyI:C
Initial studies evaluated the expression of the secreted Tr from
Ad/Tr-cells by ELISA that detects both Tr/E [6]. We report that
Ad/Tr-cells secreted significant amounts of Tr/E in an Ad-dose-
dependent manner (Figure 1A). In contrast, untreated HEC-1A
(UT) and Ad/dl-cells expressed very low to no Tr/E (Figure 1A).
Since the antibodies used in the ELISA did not distinguish Tr from
E in Ad/Tr-cells supernatants (Ad/Tr-sups), WB was performed
to clarify the presence of both Tr/E [58]. Two recombinant
reference proteins, namely commercial 66His-Tr (rTr) [15] and
in-house HAT-E (rE), were used as comparative markers for Tr
and E, respectively. Due to tag insertion, both reference proteins
appeared 3–4 kDa higher than the appearance of untagged
proteins would be expected. Thus, rE band appeared at ,10–
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,10–11 kDa was also observed in the rTr reference protein
(Figure 1B, lane 8), being most likely E present in the protein
preparation. This smaller band also appeared higher than would
be expected for E, due to the His-tag insertion. Hence, we
conclude that the commercial rTr is a mixture and contains both
Tr/E that are indicated as such on WB by arrows (Figure 1B, lane
8). WB data demonstrate that supernatants of UT and Ad/dl-cells
supernatants (Ad/dl-sups) did not show any detectable forms of
endogenous Tr/E in the blot (Figure 1B, lane 1–4). In contrast,
WB of Ad/Tr-sups in the absence of polyI:C stimulation revealed
protein bands that appeared between Tr/E bands of the reference
proteins and thus were considered as Tr (Figure 1B, lane 5). The
bands in lane 5 represent secreted Tr that resulted from Ad/Tr
infection of HEC-1A cells. Further, following polyI:C treatment of
Ad/Tr-cells, the intensity of the Tr bands in Ad/Tr-sups was
greatly increased, indicating a significantly higher amount of Tr
(Figure 1B, lane 6) being produced. Interestingly, a smaller protein
band also appeared (Figure 1B, lane 6) that was below the level of
rE-reference marker protein, as well as the E band in the rTr
reference protein (Figure 1B, lane 7), and thus was considered as
E. Taken together, these results indicate that Ad/Tr-cells secrete
Tr, and both Tr/E are detected in the supernatants following Ad/
Tr-cells stimulation with polyI:C.
Ad/Tr-cells secrete Tr that is functionally active against
HNE
Being foremost a protease inhibitor, Tr in Ad/Tr-sups was
tested in protease inhibition assay [20]. The results of anti-protease
assay showed that Ad/Tr-sups significantly inhibited HNE activity
in a dose-dependent manner, compared to Ad/dl-sups (Figure 1C).
Following polyI:C stimulation, Ad/Tr-sups, containing presum-
ably both Tr/E, were also tested and found functional against
HNE (data not shown), comparable to before polyI:C treatment
activity.
Tr/E significantly reduce VSV-GFP infection and enhance
polyI:C-driven antiviral protection in Ad/Tr-cells
Since polyI:C stimulation of ECs triggers the induction of
antiviral protection [39,44], we next determined whether Tr/E
could modulate antiviral protection. Results of standard VSV-
GFP plaque reduction assays show that the delivery of Ad/Tr
significantly reduced VSV-GFP replication in polyI:C-untreated
cells (Figure 2A and 2B) that was beyond the anti-viral protection
induced by Ad delivery alone (i.e., in Ad/dl group). Ad delivery is
known to activate innate immune responses [59], and the fact
that susceptibility of HEC-1A cells to VSV-GFP infection
(Figure 2B) was already reduced by treating the cells with Ad/
dl alone confirms the Ad-induced innate activation. Since
polyI:C-untreated Ad/Tr-cells secrete only Tr (Figure 1B), we
conclude that the presence of Tr was associated with significantly
increased antiviral protection of Ad/Tr-cells in the absence of
polyI:C. Following polyI:C treatment, VSV-GFP replication was
further reduced across the groups in Ad-cells (Figure 2A and 2B);
viral replication in Ad/Tr-cells also remained significantly
reduced (with up to 50% reduction, p,0.05) and antiviral
protection increased, compared to polyI:C-treated Ad/dl-cells
(Figure 2A and 2B). Based on these results and those shown in
Figure 1B, we deduce that the presence of both Tr/E was
associated with significantly increased cellular antiviral protec-
tion in Ad/Tr-cells after polyI:C treatment. Altogether, these
observations clearly indicate that exogenous Tr expression in
Ad/Tr-cells before VSV-GFP challenge has a separate antiviral
protective mechanism in addition to the Ad- and polyI:C-
induced responses; furthermore, both Tr/E appear to mediate
Figure 1. Ad/Tr-cells secrete Tr that is functionally active
against HNE and both Tr/E are detected in Ad/Tr-cells
supernatants in response to polyI:C. HEC-1A cells were either
treated with medium alone or with MOI 10–50 of Ad/dl or Ad/Tr.
Supernatants were collected 36 h after Ad removal and tested for Tr/E
expression by ELISA (A) or for antiprotease activity (C), where results are
expressed as percent reduction over a positive control (media alone
plus HNE and a substrate). The data are representative of two
independent experiments performed in triplicate and are shown as
the mean 6 SD. Statistical analysis was performed using Student’s t test
with * representing significant difference between the groups, p,0.05.
(B) Immunoblotting analysis of supernatants from HEC-1A cells
developed using TRAB20 antibodies. Cells were either left untreated
(lanes 1,2) or treated with MOI 50 of Ad/dl (lanes 3,4) or Ad/Tr (lanes 5,6)
and then incubated for 24 h in presence of medium alone (2)o r2 5mg/
ml polyI:C (+). Two recombinant reference proteins, namely in-house
HAT-E (rE) (lane 7) and commercial 66His-Tr (rTr) (lane 8), were used as
comparative markers for E and Tr. Bands corresponding to the forms of
Ad-induced Tr and E are indicated on the blot by arrows.
doi:10.1371/journal.pone.0035866.g001
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35866Figure 2. Tr/E significantly reduce VSV-GFP infection and enhance polyI:C-driven antiviral protection in Ad/Tr-cells. Untreated (UT) or
treated with MOI 50 of Ad/dl or Ad/Tr HEC-1A cells were medium- or polyI:C 0.1–25 mg/ml-treated for 24 h, followed by MOI 1 VSV-GFP. GFP
fluorescence intensity was visualized 24 h later using a Typhoon scanner (A), and relative fluorescence intensity to virus positive control was
determined and presented as % of UT control (B). (C) VSV-GFP load after pre-incubation of 5 mg/ml of rTr either with MOI 1 of VSV-GFP (rTr+v) or cells
(rTr+c) for 1 h, followed by their washing and addition of VSV-GFP. Medium-treated VSV-GFP (v) served as a positive control. (D) HEC-1A cells were
treated with 5 mg/ml of rTr for 1 h in serum-free medium, after which medium or 0.1 mg/ml polyI:C was added for 24 h followed by MOI 1 of VSV-GFP.
This polyI:C dose was chosen because anti-inflammatory effects of secreted/soluble proteins, compared to Ad/Tr-cells, were less potent. (E) HEC-1A
cells were pretreated with equal volumes of supernatants from Ad/dl-cells (Ad/dl-sups) and Ad/Tr-cells (Ad/Tr-sups, 5 mg/ml final concentration) for
1 h before medium or 0.1 or 5 mg/ml polyI:C was added for 24 h followed by MOI 1 VSV-GFP. Lower polyI:C doses were used to better visualize VSV-
GFP viral replication 24 h later, using a Typhoon scanner. Insert in panel (E) depicts VSV-GFP load after pre-incubation of same volumes and
concentrations of Ad/dl- and Ad/Tr-sups with either MOI 1 VSV-GFP (dl+v) or (Tr+v), respectively, or cells (dl+c) or (Tr+c) for 1 h, followed by washing
and addition of MOI 1 VSV-GFP. Medium-treated VSV-GFP (v) served as an untreated control. The data are representative of at least two independent
experiments performed in triplicate and shown as mean 6 SD. Statistical analysis was performed using ANOVA or Student’s t test in (C), and *
representing significant difference, when p,0.05. (F and G) Cell growth and metabolic activity of HEC-1A cells were determined by standard MTT Cell
Viability Assay Kit following infection with MOI 10–50 of Ad/dl or Ad/Tr (F) or after stimulation with increasing doses of polyI:C (G). Cell viability was
expressed as % of untreated cells, which served as a negative control group, and was designated 100%; the results are expressed as % of negative
control.
doi:10.1371/journal.pone.0035866.g002
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cells.
We next attempted to elucidate specific mode(s) of Tr/E
antiviral activity. Given the possibility of additional Tr/E being
released from Ad/Tr-cells after polyI:C stimulation and upon
VSV-GFP challenge and thus potentially acting on both virus and
cells, we tested if both or each Tr/E individually were acting
through two separate mechanisms: (i) direct antiviral activity
exerted during the virus/cell encounter and viral binding/entry,
targeting either virus or cells; and (ii) indirect cell-associated
immunomodulatory activity that targets polyI:C-triggered cellular
antiviral responses and protection. To minimize the Ad-associated
effects, we used secreted/soluble proteins delivered to Ad-
uninfected HEC-1A cells. Because we could not use Ad/Tr-sups
after polyI:C stimulation as a source of both Tr/E, since they
would contain residual polyI:C and thus mask the effect of Tr/E
alone, a commercial rTr (with a C-terminus His-tag) was used as a
source of both Tr/E, based on results shown in Figure 1B. For
comparative assessment of each Tr/E individually, we used Ad/
Tr-sups before polyI:C stimulation as a source of secreted Tr (no
tag), and rE (with an N-terminus HAT-tag) was used as a source of
E. All the proteins were initially compared for their antiprotease
activity and found equally potent against HNE at around 10 mg/
ml (data not shown). Figure 2C shows that when virus, but not
cells, was pre-treated with recombinant rTr for 1 h before addition
onto cells, viral replication was significantly reduced by about 20%
(p,0.05), compared to media alone. Of note, no further reduction
in viral replication was noticed when a higher dose of rTr was
used. These results clearly indicate that rTr (a mixture of Tr/E)
has a statistically significant, albeit modest, antiviral effect, which
appears to be due to direct, or virus-mediated, activity of the
proteins. We further show that pretreatment of HEC-1A cells with
rTr, followed by co-culturing with polyI:C for 24 h before VSV-
GFP challenge, significantly reduced viral replication (up to 30%,
p,0.05) and enhanced polyI:C-induced antiviral protection,
compared to polyI:C alone (Figure 2D). Interestingly, when cells
were pretreated with rTr, then washed and challenged with VSV-
GFP 24 h later without prior polyI:C stimulation, no significant
decrease in viral replication was observed (data not shown),
suggesting that rTr does not induce potent antiviral cellular
responses without polyI:C stimulation and reduces VSV-GFP
replication only following direct contact with virus. Collectively,
these results suggest that secreted/soluble rTr, as a mixture of both
Tr/ E, demonstrated two distinct properties: a virus-mediated
antiviral activity and the modulation/enhancement of polyI:C-
induced cellular antiviral responses, suggesting that the presence of
both Tr/E is required for both of these activities.
Next we assessed antiviral properties of individual secreted/
soluble Tr/E preparations. We show that VSV-GFP replication
was reduced (up to 40%, p,0.05) in Ad/Tr-sups-treated cells
(Figure 2E), compared to controls, but only after polyI:C
treatment (Figure 2E, main graph and insert), suggesting that Tr
from Ad/Tr-sups does not exhibit potent direct antiviral activity,
but is capable of enhancing polyI:C-induced cellular responses.
Insert in Figure 2E demonstrates that, although a trend toward a
decreased viral replication was noted when Ad/Tr-sups were pre-
incubated with the virus, there was no significant inhibitory effect
observed from Ad/Tr-sups, compared to their controls. Further-
more, surprisingly, in contrast to rTr or Ad/Tr-sups, rE did not
exhibit any antiviral properties (data not shown), indicating
differential antiviral properties of the tested proteins that could
be potentially related to their structural differences. Collectively,
these results clearly indicate that both Tr/E appear to be required
for antiviral protection mediated via both mechanisms.
Exogenous expression of Tr and polyI:C stimulation do
not lead to impaired cell viability or metabolic activity of
Ad/Tr-cells
Considering that polyI:C can induce apoptosis [60], we
determined whether Ad/Tr-cells had impaired cell viability and
metabolic activity, using a standard MTT Cell Viability Assay
[39]. Our results determined no significant changes in viability and
metabolic activity among the groups following either Ad, with
recovery period of 4 h versus 24 h (data not shown), or polyI:C
treatment (Figure 2F and 2G). Therefore, we can exclude the
impairment in the treated cells as the cause of differences between
Ad/Tr- and Ad/dl-cells.
Ad/Tr-cells respond to polyI:C treatment with modulated
production of IFNb
We next elucidated the immunomodulatory effect of Tr/E in
Ad/Tr-cells in context of polyI:C stimulation. Type I IFNs are
considered a hallmark of antiviral response, with IFNb being a key
correlate of polyI:C-induced antiviral protection [39,40,44]. We
determined whether enhanced antiviral protection in presence of
Tr/E was associated with higher levels of IFNb, using quantitative
real-time RT-PCR and commercial ELISA. Figure 3 demon-
strates that polyI:C treatment of Ad-cells triggered a significant
induction of IFNb expression/secretion in contrast to untreated
Ad-cells. Interestingly, Ad/Tr-cells responded to polyI:C treat-
ment with significantly dampened, but not completely abrogated,
levels of IFNb, compared to Ad/dl-cells. Since IFNb levels were
reduced at both mRNA (Figure 3A) and protein (Figure 3B) levels,
it is likely that IFNb expression was affected primarily at the
transcription level. A similar dampening effect was observed when
IFNb protein was assessed at earlier time point (6 h) or in response
to a lower dose of polyI:C (0.1 mg/ml) (data not shown). We have
also attempted to measure other members of type I IFNs as well.
Namely, multi-subtypes of IFNa were measured by commercial
ELISA [61]; however, levels of proteins detected in all superna-
tants were below the sensitivity of the ELISA and thus considered
undetectable (data not shown).
Enhanced polyI:C-driven antiviral protection is associated
with hyperactivation of IRF3 in Ad/Tr-cells
Phosphorylation and nuclear translocation of IRF3 are key
events in the transcriptional activation of inducible ISG cellular
genes [44,48], and polyI:C was previously shown to induce
activation of IRF3 in vitro [39,44]. Qualitative and quantitative
analyses of phosphorylated IRF3 (pIRF3) showed that, compared
to control cells, IRF3 phosphorylation in Ad/Tr-polyI:C-treated
cells was initially modestly reduced at 1 h, but then subsequently
increased after 2 h (Figure 4A, pIRF3 WB panel and quantifying
histogram) and remained increased for up to 24 h (data not
shown). In contrast, no significant changes were evident in the
total IRF3 (tIRF3) protein amount for Ad/Tr-cells, compared to
controls (Figure 4A, tIRF3 WB panel). Confocal imaging at 4 h
post polyI:C stimulation (Figure 4B) corroborated WB findings of
increased IRF3 phosphorylation in Ad/Tr-cells, since significantly
more Ad/Tr-cells appeared with IRF3 translocated into the
nucleus, compared to Ad/dl-cells (Figure 4B, polyI:C panel).
Taken together, these results suggest that exogenous expression of
Tr/E promotes hyperactivation of IRF3 that is associated with
increased antiviral protection of Ad/Tr-cells against VSV-GFP
challenge.
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Ad/Tr-cells following polyI:C stimulation
ISG15 and ISG56 have been implicated in antiviral protection
and linked to activation of IRF3 in response to polyI:C [44,62].
Results of RT-PCR demonstrated no difference in mRNA levels of
ISG15 between Ad/Tr and Ad/dl groups after polyI:C stimula-
tion (data not shown). In contrast, mRNA expression of ISG56
(Figure 5A and 5B) appeared significantly reduced in Ad/Tr-cells
in response to polyI:C.
Tr/E alter phosphorylation and transcriptional activity of
NF-kB in Ad/Tr-cells in response to polyI:C
We next elucidated phosphorylation and activation of other
transcription factors, including NF-kB and c-Jun, that have also
been shown to contribute to antiviral responses [38,41,45].
Qualitative and quantitative results show that NF-kB p65
phosphorylation in Ad/Tr-cells was attenuated after 1 h post-
polyI:C exposure and remained decreased until 8 h, compared to
the control group (Figure 6A, NF-kB WB panel and Figure 6B,
NF-kB quantifying histogram). Our results further revealed that
overall c-Jun phosphorylation was only transiently reduced in Ad/
Tr-cells between 1 h and 4 h and returned to levels comparable to
such of controls at 8 h post polyI:C treatment (Figure 6A, pc-Jun
WB panel and Figure 6B, pc-Jun quantifying histogram). These
results prompted us to next evaluate the effect of Tr expression on
transcriptional activity of NF-kB and c-Jun, which was assessed by
luciferase reporter gene assay. Data shown in Figure 6C, NF-kB/
Luc panel, demonstrate that transcriptional activity of NF-kBi n
Figure 3. Ad/Tr-cells respond to polyI:C treatment with
reduced production of IFNb. HEC-1A cells were either treated with
medium alone (UT) or with MOI 50 of Ad/dl or Ad/Tr and incubated for
6–24 h in presence of media or 25 mg/ml of polyI:C. (A) At 6 h post
treatment, IFNb mRNA from total RNA was determined by real-time
quantitative RT-PCR. Values are normalized to a housekeeping gene 18S
in the same sample and presented as fold induction over UT cells in
absence of polyI:C treatment. (B) At 24 h of polyI:C stimulation,
supernatants were tested for IFNb expression by ELISA. Data are
representative of at least two independent experiments performed in
triplicate and expressed as the mean 6 SD, shown in pg/ml. Statistical
analysis was performed using Student’s t test with * representing
significant difference between the groups, p,0.05.
doi:10.1371/journal.pone.0035866.g003
Figure 4. Enhanced polyI:C-driven antiviral protection in Ad/
Tr-cells is associated with hyperactivation of IRF3. (A) Western
blots and their analyses of phosphorylated IRF3, total IRF3, and GAPDH
proteins were performed from whole-cell extracts of HEC-Ad cells that
were either left untreated or treated with 25 mg/ml polyI:C during
indicated time points. (B) Immunofluorescence analysis of IRF3 nuclear
translocation following either medium alone or polyI:C 25 mg/ml
treatment for 4 h. Representative staining is shown for IRF3 (green),
nuclear stain (PI) (red), and composite (yellow) at magnification 25206.
The data are representative of three independent experiments with
similar results.
doi:10.1371/journal.pone.0035866.g004
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compared to untreated and LPS-treated Ad/dl-cells. However,
polyI:C-induced NF-kB transcriptional activity in Ad/Tr-cells was
significantly reduced, compared to Ad/dl-cells. In contrast,
transcriptional activity of AP-1 was not different between the
groups following stimulation with either of the ligands (Figure 6C,
AP-1/Luc panel). Collectively, our data show that Tr/E
expression attenuated NF-kB activation not only at the phosphor-
ylation level, but also at the level of its transcriptional activity,
which was more pronounced compared to changes observed for c-
Jun/AP-1.
Tr/E significantly reduce levels of dsRNA sensors RIG-I
and MDA5 in polyI:C-treated Ad/Tr-cells
PolyI:C-induced antiviral protection of primary genital ECs was
previously associated with heightened expression of TLR3 [40].
Thus, we evaluated the expression levels of dsRNA sensors in Ad/
Tr-cells following polyI:C treatment. Figures 6D–F show that in
contrast to TLR3, polyI:C stimulation induced a significant (over
40 times) increase in mRNA expression of RIG-I and MDA5
(Figure 6D–E, left panels) in all UT and Ad-cells. Further,
compared to UT and Ad/dl-cells, Ad/Tr-cells surprisingly had
significantly attenuated expression of RIG-I and MDA5 at both
mRNA and protein levels (Figure 6D–E, left and right panels).
RIG-I expression in Ad/Tr-cells appeared to be affected at earlier
time point, around 1 h, compared to MDA5 expression that was
attenuated at 8 h after polyI:C stimulation. Moreover, reduced
expression levels of RIG-I and MDA5 were sustained for up to
24 h following polyI:C treatment (data not shown). The expression
of TLR3, however, was not different between the groups
(Figure 6F). Collectively, these data indicate that mRNA and
protein expression of RIG-I and MDA5 are increased in response
to polyI:C stimulation, but the magnitude of expression is reduced
in Ad/Tr-cells. Further, that we observed differential pattern of
expression among RIG-I, MDA5, and TLR3 could indicate either
a different kinetics of responses of these sensors, or that each RIG-
I, MDA5, and TLR3 respond differentially to polyI:C, known to
be a mixture of various lengths of dsRNA [43].
IRF3 is required for polyI:C-driven antiviral protection in
Ad/Tr-cells
We next determined whether IRF3 was required for enhanced
polyI:C-driven antiviral state in Ad/Tr-cells. IRF3 was knocked
down by utilizing IRF3-specific small interfering RNA and cells
were subsequently treated, or not, with polyI:C before challenging
with VSV-GFP. The greatest knockdown efficiency was observed
between 72 h and 96 h post transfection (data not shown). Results
of WB demonstrated no apparent expression of tIRF3 after siRNA
treatment (Figure 7A). Further, VSV-GFP replication in polyI:C-
untreated Ad/dl- and Ad/Tr-cells was not significantly altered
when IRF3 was knocked down (Figure 7B). This observation
suggests that IRF3 is dispensable for antiviral defense against
VSV-GFP infection in both Ad/dl and Ad/Tr groups in the
absence of polyI:C treatment and that markedly reduced viral
replication in Ad/Tr-cells was attributed to other, yet unidentified,
factor(s). In contrast, when polyI:C was added, VSV-GFP
replication was initially markedly reduced in both Ad/dl and
Ad/Tr groups in the presence of IRF3, but then significantly
increased in the absence of IRF3; yet, Ad/Tr-cells still remained
more protected than Ad/dl group. This observation implies that
enhancement of polyI:C-triggered antiviral protection in Ad/Tr-
cells was only partially dependent on IRF3. Figure 7B also showed
that VSV-GFP replication was restored about 50% of the original
viral load detected in each of the groups in absence of IRF3 and
polyI:C stimulation, suggesting that additional mechanisms/
factors were contributing to polyI:C-induced antiviral protection.
Collectively, these findings indicate that IRF3 plays an equally
important role in antiviral protection in both Ad/dl and Ad/Tr
groups, and that the presence of IRF3 is important, but not
essential, for enhanced polyI:C-induced antiviral protection in
Ad/Tr-cell, as other factors, perhaps upstream of IRF3, may also
be contributing to this protection.
Tr/E significantly reduce pro-inflammatory cytokines in
ECs following polyI:C and LPS stimulation
PolyI:C stimulation induces not only antiviral, but also pro-
inflammatory factors [39,40] that are regulated by viral sensors
and transcription factors, including NF-kB and c-Jun. We
therefore assessed levels of pro-inflammatory mediators IL-8,
TNFa, and IL-6 in Ad/Tr-cells treated with polyI:C. Figures 8A–
C demonstrate that Ad/Tr-cells, regardless of their origin (i.e.,
genital HEC-1A or gut Caco-2, etc.), secreted significantly lower
levels of IL-8 24 h after polyI:C and LPS treatment, compared to
controls; TNFa and IL-6 were similarly reduced in Ad-cells in
response to polyI:C (data not shown). Interestingly, stimulation of
HEC-1A with LPS did not produce a significant increase in IL-8,
compared to untreated cells, possibly due to a low baseline
expression of TLR4 in the genital EC [39]. These results clearly
Figure 5. Exogenous expression of Tr/E significantly decreases
mRNA expression of ISG56 in Ad/Tr-cells following polyI:C
stimulation. HEC-1A cells were either treated with medium alone or
with MOI 50 of Ad/dl or Ad/Tr and incubated in presence of media or
25 mg/ml of polyI:C. (A) At 6 h post treatment, total RNA was harvested
and mRNA levels of ISG56 were assessed by conventional RT-PCR. (B)
Quantification of ISG56 expression using ImageQuant software. Values
are normalized to a housekeeping gene 18S in the same sample and
presented as relative fold induction over untreated cells, shown in
arbitrary units. The data are representative of at least two independent
experiments performed in triplicate and are shown as the mean 6 SD.
Statistical analysis was performed using Student’s t test with
* representing significant difference between the groups, p,0.05.
doi:10.1371/journal.pone.0035866.g005
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mediators in ligand-treated cells. Interestingly, Tr/E secreted by
Ad/Tr-cells appeared to significantly contribute to reduced IL-8
levels. Indeed, Tr/E neutralization with specific anti-Tr/E
TRAB20 (HyCult Biotech) antibodies (under the control of
antiprotease assay) that were added to Ad/Tr-cells 1 h prior to
0.1 mg/ml of polyI:C treatment and subsequently co-cultured with
polyI:C for additional 24 h to neutralize any secreted Tr/E, led to
significantly higher polyI:C-induced IL-8 secretion (up to 40%,
p=0.03) in Ad/Tr-cells (data not shown). Figures 8D and 8E
further show that HEC-1A cells pre-treated with either Ad/Tr-
sups, rTr or rE before subsequent co-culture with polyI:C also
released lower levels of IL-8 in response to polyI:C. Of note, anti-
inflammatory effects of secreted/soluble proteins, compared to
Ad/Tr-cells, appeared to be less potent and context-dependent,
which forced us to use a lower dose of 0.1 mg/ml of polyI:C.
Additionally, either Ad/Tr-sups or rTr/rE alone did not trigger
any significant IL-8 production in absence of polyI:C. Collectively,
our findings indicate that Tr/E are capable of inhibiting
inflammatory responses in ECs from various sources and against
both viral and bacterial PAMPs, and that secreted/soluble Tr/E
significantly contribute to reduction in polyI:C-induced IL-8
secretion. However, stimulation of immune responses can also
be observed depending on experimental conditions.
Discussion
WAP proteins, including antiproteases Tr/E, SLPI, and ps20,
are pleiotropic molecules known to play multiple and significant
roles in health and disease [8,10,11]. Indeed, ps20 has been
reported as a potential diagnostic marker in prostate cancer [63]
and as a novel negative signature protein in HIV infection [64]. In
contrast, SLPI and Tr/E show significant therapeutic potential in
atherosclerosis as well as cardiovascular [25,65,66,67], lung
[68,69] and gut disorders [66,70]. Additionally, higher levels of
Tr/E in CVLs of HIV-resistant CSWs [29] and the testing of the
Lactobacilli-based elafin delivery system for combating STIs in the
FGT [71] would further support this notion. Our data showed that
delivery of Ad/Tr to HEC-1A cells resulted in secretion of
functional Tr, while both Tr/E were detected following treatment
of these cells with polyI:C. Moreover, polyI:C treatment further
resulted in Tr/E-enhanced antiviral protection and significantly
reduced pro-inflammatory IL-8, IL-6, TNFa that were associated
with lower expression of viral innate sensors RIG-I and MDA5
and altered NF-kB activation in Ad/Tr-cells. Notably, increased
antiviral protection was due in part to Tr/E ability to act directly
on virus or by modulating polyI:C-driven cellular antiviral
responses. Interestingly, such Tr/E-augmented cellular responses
triggered by polyI:C were partially mediated through IRF3
activation, but not higher induction of IFNb, thus suggesting
multiple antiviral mechanisms of Tr/E and the involvement of
alternative and still unidentified factors or pathways.
This is the first study that comparatively assessed the presence
and potential mechanisms of antiviral activity of each Tr/E. Here,
we presented evidence showing two distinct, but likely compli-
mentary antiviral properties of Tr/E: (i) direct antiviral activity
exerted during the virus/cell interaction and targeting virus, but
not cells; and (ii) indirect and cell-associated immunomodulatory
activity, targeting polyI:C-triggered cellular antiviral responses.
The virus-mediated activity was observed in the absence of
polyI:C stimulation and in the presence of Tr in Ad/Tr-cells
(presumably present in both Ad/Tr-sups and Ad/Tr-cells).
Because only Tr was detected in polyI:C-untreated Ad/Tr-cells,
and because the expression of IFNb was low and not different
Figure 6. Altered NF-kB phosphorylation and transcriptional activity and reduced RIG-I and MDA5 expression in polyI:C-treated
Ad/Tr-cells. Western blots (A) and their quantification (B) of phosphorylated p65 subunit of NF-kB (pNF-kB) as well as c-Jun (pc-Jun) and GAPDH
proteins were performed from whole-cell extracts of Ad-cells that were either left untreated or treated with 25 mg/ml polyI:C during indicated time
points. Transcription activity (C) of NF-kB (NF-kB/Luc panel) and (AP-1/Luc panel) was assessed by luciferase reporter assay by transfecting HEC-1A
cells with pgkb-Gal and pNF-kB-Luc or pAP-1-Luc plasmids (total DNA 40 ng per well) (p) alone or together with 50 MOI of Ad/dl or Ad/Tr overnight,
washing, allowing to rest for 4 h and stimulating with 25 mg/ml polyI:C and 1 mg/ml LPS for 4 h. Then luciferase and b-galactosidase activities were
determined in cell lysates and expressed as relative luciferase units using galactosidase plasmid as normalization control. Data are presented as mean
6 SD and are representative of three experiments for NF-kB and two - for AP-1. (D–F, left panels) Total RNA was harvested and mRNA expression of
RIG-I, MDA5, and TLR3 was determined by real-time quantitative RT-PCR at 6 h post treatment with polyI:C 25 mg/ml. Values are normalized to a
housekeeping gene 18S in the same sample and presented as fold induction over untreated cells. (D–F, right panels) Western blot analysis of RIG-I,
MDA5, TLR3, and GAPDH protein was performed from whole-cell extracts of Ad-cells that were either treated or not with 25 mg/ml polyI:C during
indicated time points. The data are representative of at least two independent experiments performed in triplicate and are shown as the mean 6 SD.
Statistical analysis was performed using Student’s t test with * representing significant difference between the groups, p,0.05.
doi:10.1371/journal.pone.0035866.g006
Figure 7. IRF3 is required for polyI:C-driven antiviral protection
in Ad/Tr-cells. (A) HEC-1A cells were left untreated or transfected with
a non-targeting control siRNA (ctrl siRNA), or IRF3 siRNA (IRF3 siRNA) for
48 h. Two days after siRNA delivery, HEC-1A received MOI 50 of Ad/dl or
Ad/Tr followed by 25 mg/ml of polyI:C treatment for 24 h and Western
blot analyses of total IRF3 (tIRF3) and GAPDH proteins were performed
from whole-cell extracts 96 h post-transfection. (B) Twenty four hours
following polyI:C treatment, cells were infected with MOI 1 of VSV-GFP
for another 24 h. Levels of GFP fluorescence were visualized and
quantified using a Typhoon scanner. The fluorescence reading of
treated cultures was normalized to untreated (control) cultures and
presented as percentage relative fluorescence. The data are represen-
tative of two independent experiments performed in triplicate and are
shown as the mean 6 SD. Statistical analysis was performed using
Student’s t test with * representing significant difference between the
groups, p,0.05.
doi:10.1371/journal.pone.0035866.g007
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the absence of polyI:C, Tr alone was mediating antiviral activity in
Ad/Tr-cells by acting either directly on virus or indirectly through
cells. However, we failed to transfer this direct antiviral effect of Tr
via Ad/Tr-sups, possibly due to the absence of an additive
protective effect from augmented intracellular Tr (as would be
expected in Ad/Tr-cells),or due to an inefficient delivery of Tr in
supernatants and a ‘‘diluting’’ effect from other antiviral factors
released in response to Ad/dl delivery (Fig. 2E, insert).
Additionally, the presence of both Tr/E, as in rTr preparation,
was also protective against VSV-GFP challenge in the absence of
polyI:C treatment. Although no reports describing direct antiviral
activity of Tr are published to date and no precise mechanisms of
Tr/E direct antiviral effect have been identified, our observation
with rTr is in line with Ghosh et al. findings, describing a direct
antiviral effect of E as a mode of action against HIV [6].
Interestingly, rTr also appeared to have only virus- and not cell-
mediated protective effects, similar to E mentioned earlier [6]. In
contrast, a close WAP member SLPI, was shown to have only cell-
mediated antiviral effects, at least against HIV [72] and herpes
simplex virus (HSV) [73]. Examples of same-family members
having differential antiviral mechanisms have also been described
for other innate molecules, such as human defensins against HIV
[74,75] and HSV [76]. These reports suggest that molecules even
from the same group, may possess their own, potentially different
in potency and targets, exquisite antiviral activities and yet still
uniquely contribute to overall mucosal protection against STIs.
Our results further suggest that the presence of both Tr/E
might be required for each virus- (direct) and cell-associated
(indirect) antiviral effect, as was evident from our data using Ad/
Tr-cells, Ad/Tr-sups, and rTr, indicating that perhaps the most
efficient antiviral protection depends on collaborative work of both
Tr/E. Interestingly, when HIV-susceptible, but uninfected, CSWs
were followed prospectively, those who remained HIV-negative
had elevated levels of both Tr/E detected in CVLs [29].
Additionally, when characterizing the specificity of proteins
secreted after Ad/Tr infection, our ELISA and WB results also
showed that Ad/Tr-cells secreted both Tr/E independently in
response to polyI:C, while only Tr was detected without polyI:C
stimulation. Although Ghosh et al. also reported that primary
uterine EC produced Tr/E in response to polyI:C [6], the
independent production of E was never demonstrated. Further,
only Tr (13–16 kDa) was previously identified in supernatants
from LPS-stimulated alveolar ECs [37]. On conjuncture, these
Figure 8. Tr/E significantly reduce protein secretion of IL-8 in ECs following polyI:C and LPS stimulation. Secretion of IL-8 in
supernatants from HEC-1A (A), A549 (B), and Caco-2 (C) cells initially infected with MOI 50 of Ad/dl or Ad/Tr and subsequently stimulated with either
25 mg/ml of polyI:C or 1 mg/ml of LPS for 24 h. Following stimulation, supernatants were tested for IL-8 secretion by ELISA. Data are representative of
at least two independent experiments performed in triplicate and expressed as the mean 6 SD, shown in pg/ml. Statistical analysis was performed
using Student’s t test with * representing significant difference between the groups, p,0.05. (D) Secretion of IL-8 in supernatants from HEC-1A cells
that were pre-treated with HEC-Ad/dl and HEC-Ad/Tr supernatants before polyI:C stimulation. HEC-1A received 50 ml of concentrated supernatants
containing around 10 mg/ml of Tr/E in Ad/Tr supernatants and 0.004 mg/ml of Tr/E in Ad/dl sups for 1 h, to which additional 50 ml of medium alone or
polyI:C to the final concentration of 0.1 mg/ml were added for 24 h. (E) Secretion of IL-8 in supernatants from HEC-1A cells treated with commercial
66His-Tr (rTr) or in-house HAT-E (rE) for 1 h and then stimulated with medium alone or 0.1 mg/ml of polyI:C for 24 h. A lower dose of polyI:C was used
in (D) and (E), since anti-inflammatory effects of secreted/soluble proteins, compared to Ad/Tr-cells, were less potent. Statistical analysis was
performed using ANOVA, and * representing significant difference between the polyI:C group and rTr groups; { representing significant difference
between the polyI:C and rE groups, p,0.05.
doi:10.1371/journal.pone.0035866.g008
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or ligand-specific defense mechanism against an unknown
protease that was potentially activated in response to a viral
ligand. It might be important in the future to clarify whether
primary genital EC from the FGT produce each Tr/E
independently in response to polyI:C, similarly to Ad/Tr-cells.
It is unclear why tested rE failed to show antiviral activity
against VSV-GFP; it could be attributed, however, to a HAT-tag
insertion at the N-terminus of rE. Indeed, all rTr, rE, and secreted
Tr were equally functional against HNE (data not shown) and
capable of inhibiting IL-8 production in response to polyI:C
(Figure 8). Yet, while rTr with a His-C-terminus tag exhibited
antiviral activity, rE with a HAT-N-terminus tag did not. This
observation suggests that blocking N-terminus, but not C-
terminus, appears to be critical for antiviral activity of rE. An
earlier study by McMichael et al. supports this argument, since
they showed that the N-terminus of Tr had a better affinity for
LPS than its C-terminus end [28]. Additionally, it is unclear why
we observed increased levels of IL-8 with higher concentrations of
rTr and rE. But one possible explanation could be that the
proteins were initially delivered and left on cells in serum-free
conditions, thus promoting the activation of pro-inflammatory
events as was previously shown for Tr/E in response to LPS [28].
The second antiviral property of Tr/E observed in our study
was an indirect cell-mediated immunomodulatory activity of Tr/
E, targeting polyI:C-induced antiviral cellular responses. In
contrast to responses to bacterial or pro-inflammatory stimuli
[25,26], the scope and specific mechanism(s) of viral ligand-
triggered immunomodulatory activity of Tr/E have never been
fully investigated. Our data demonstrate that this indirect cell-
associated activity is targeting viral recognition through modula-
tion of RNA helicase expression as well as the induction of key
inflammatory and antiviral innate signaling pathways and
mediators.
Our results showed that polyI:C-triggered antiviral cellular
protection was significantly enhanced in the presence of Tr (in
Ad/Tr-sups) and Tr/E (in Ad/Tr-cells and in rTr). We also
showed that polyI:C-mediated activation of IRF3 was further
induced in Ad/Tr-cells, compared to controls, whereas IFNb
expression was dampened. Interestingly, human b defensin 3 [77]
and cathelicidin LL37 [78] that were previously shown to have
antiviral, including anti-HIV, activity [79,80], were also reported
to inhibit IFNb production in vitro in response to LPS and polyI:C,
respectively. These observations further support our results and
strengthen the earlier argument of Tr/E acting either directly
against VSV-GFP or through cells and additional factors/
pathways in Ad/Tr-cells. Furthermore, moderation of immune-
inflammatory responses and thus curbing undesirable immune
activation might be one of the protective mechanisms of innate
antimicrobials at mucosal sites. Additionally, in searching for ISGs
typically associated with antiviral protection and IRF3 activation
[62], we found that expression of ISG15 was not significantly
changed, unlike ISG56 being reduced and in agreement with
IFNb data. It is not entirely understood why such discordance was
observed; however, it could be due to the fact that ISG15 was
shown to be regulated by either IRF3 or IFNb [44,81], unlike
ISG56 that was shown to be under the regulation of IFNb or
viruses [82,83] and thus following IFNb pattern of induction as
shown in our study. The alternative explanation could be that
these two genes follow a different temporal pattern of activation
that was overlooked here.
This is the first report on the involvement of serine
antiproteases, Tr/E in particular, in antiviral signaling pathways.
As no prior data are available on the role of Tr/E in IFNb and
IRF3 induction, further and more detailed investigations might be
required to explain why in Ad/Tr-cells IFNb and ISG56 levels
were reduced while IRF3 activation was increased. We hypoth-
esize, however, that this phenomenon could be an attempt of Tr/
E to control antiviral inflammatory events through RIG-I/MDA5
and NF-kB downregulation while increasing cellular protection
through activation of IRF3 and/or alternative factors or pathways.
Although most of the studies show ISG56 to be associated with
upregulated IRF3 [62], our finding is in line with data from Li et al.
showing that a knockdown of ISG56 was associated with increased
IRF3 activation and inhibition of VSV-GFP replication [84] as a
result of ISG56 mediating MITA-TBK1 interaction and subse-
quent downstream activation of IRF3. It is also possible that
alternative factors/pathways, in addition to IRF3, regulate IFNb
and ISG56 expression and contribute to Tr/E-enhanced antiviral
protection, which is also supported by our IRF3 siRNA data.
Collectively, these data indicate that in the presence of Tr/E,
antiviral protection is increased and that direct or indirect antiviral
effect(s) of Tr/E depend, but not exclusively, on IRF3 and other
factors, perhaps upstream of IRF3.
Inflammation is one of the leading factors predisposing to
acquisition and disease progression of STIs in the FGT [52,53,85].
This notion is supported by the fact that ‘‘immune quiescence’’
and reduced immune activation are crucial for resistance against
STIs [86], while dysregulated TLR expression and immune-
inflammatory responses are detrimental [52,53,85]. Here, we
showed that Tr/E individually or as a mixture, as well as in Ad/
Tr-cells and as secreted/soluble proteins in Ad/Tr-sups, were
capable of reducing IL-8, IL-6, and TNFa expression in response
to polyI:C. Moreover, in Ad/Tr-cells we also observed signifi-
cantly reduced activation and transcriptional activity of NF-kB.
The IL-8 inhibitory effect was not specific to human endometrial
ECs, or to polyI:C, indicating that similar effects could be
observed at other mucosal surfaces and in response to different
microbial ligands. We further showed that, compared to controls,
mRNA and protein levels of RIG-I and MDA5 (mainly at a later
time point), but not TLR3, were significantly diminished in
response to polyI:C and in presence of Tr/E. Immunomodulatory
properties of both Tr/E demonstrated in models of pro-
inflammatory and bacterial (LPS) stimulations were shown to
depend on inhibition of NF-kB and AP-1 activation [25,26], thus
further supporting our NF-kB data. However, Tr/E inhibitory
effect targeting antiviral immune responses, including viral
sensing, has not been previously reported. Hence, modulation of
expression of RIG-I, MDA5, and pro-inflammatory mediators
shown here could represent novel antiviral functions of Tr/E,
possibly even executed at different levels, namely receptors and
transcription factors. That we observed differential pattern of
RIG-I, MDA5, and TLR3 expression could indicate either
different temporal kinetics of responses of these sensors, or that
each RIG-I, MDA5, and TLR3 respond differentially to polyI:C,
being a mixture of variable lengths of dsRNA [43]. Further, the
lack of polyI:C-triggered TLR3 induction in HEC-1A compared
to primary genital ECs, also likely reflects tissue or structure-
dependent differences between the cells, suggesting that primary
genital ECs may exhibit distinct results. Collectively, these
observations suggest that Tr/E can alter innate viral recognition
and mounting of antiviral immune-inflammatory responses.
The precise mechanism(s) of immunomodulatory effects of Tr/
E, as both secreted and/or intracellularly expressed proteins, on
viral sensors, cytokines, and IFNb in response to polyI:C treatment
is still largely unknown. This is partly because the existence of the
cognate receptor for Tr/E remains elusive, and it is equally
unknown whether Tr/E require a receptor to function. We
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Tr cells in response to polyI:C are likely a result of overall
attenuation of RIG-I and MDA5 levels, as they are known to
regulate the expression of pro-inflammatory and antiviral
mediators [4,41,87] through activation of main signaling path-
ways, such as NF-kB that is downregulated in our study [41]. It
remains to be elucidated, however, how Tr/E specifically inhibit
RIG-I and MDA5 expression. It is plausible that Tr/E directly
bind to polyI:C, as was shown for binding of LL37 to polyI:C [78],
as well as Tr/E binding to LPS [28]. Such an interaction may alter
binding/recognition of polyI:C by its cognate receptors, including
cell-surface scavenger receptor A or intracellular sensors RIG-I,
MDA5, and TLR3, which in turn could explain our reduced
expression levels of RIG-I and MDA5. Another possible site of
inhibition by Tr/E could be downstream of receptors/viral sensors
and involve Tr/E binding to DNA and competing for specific
DNA binding sites with transcription factors including NF-kB, as
was shown for SLPI as one of its anti-inflammatory mechanisms in
response to LPS [88].
A noteworthy observation of this study is that while Tr from
Ad/Tr-sups and rE were found functional against HNE and able
to inhibit polyI:C-induced IL-8 production, they did not show any
antiviral activity, suggesting that antiprotease, anti-inflammatory,
and antiviral activities of the tested proteins may not necessarily be
co-dependent or predictive of each other; nonetheless, they can be
complimentary. This observation is supported by earlier reports,
showing both a protease non-inhibitory N-terminus and an
inhibitory C-terminus of Tr exhibiting comparable antibacterial
and antifungal functions [22,24]. In contrast, Mulligan et al.
showed that SLPI Gly(72) mutant, unlike other mutants tested in
that study, lost its in vivo immunosuppressive activity against NF-
kB activation and neutrophil recruitment in the lungs that
appeared to be most closely related to SLPI’s trypsin-inhibiting
activity [89]. Although being an important property of both Tr/E,
the inhibition of HNE activity is not considered a critical function
for our studies, since epithelial cells do not make neutrophil
elastase [90] and thus, the earlier discussed Tr/E-mediated
changes are most unlikely attributed to antielastase activity of
the proteins. The above observations indicate that perhaps
additional structure-function studies might be warranted in the
future to specifically address the cross-talk between antiprotease,
anti-inflammatory, and antiviral properties of Tr/E and their
specific roles in defense against viruses.
Overall, our data support and further extend earlier observa-
tions on immunomodulatory effects of Tr/E [25,26]. This work
demonstrates that in genital ECs and in response to polyI:C, Tr/E
antiviral effects are mediated through direct or virus targeting
activity and indirect or cell-associated immunomodulatory func-
tion(s) that target host innate recognition and mounting of antiviral
and inflammatory responses. While dampening of IFNb, a key
antiviral mediator, may seem counterintuitive and detrimental to
antiviral defenses, our findings suggest that directly or indirectly
increased antiviral protection and moderated, or finely-tuned,
inflammation, might be more advantageous to a host in the
context of viral exposure. In conclusion, this study clearly
demonstrates the importance of Tr/E in antiviral protection.
Our findings also propose the existence of multiple targets and
potentially several and unique modes of action for each of the
proteins, which warrant additional research in the future.
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